SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-23-276713
Filing Date
2023-11-14
Accepted
2023-11-14 09:03:20
Documents
58
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d483795d10q.htm   iXBRL 10-Q 1297317
2 EX-31.1 d483795dex311.htm EX-31.1 6606
3 EX-31.2 d483795dex312.htm EX-31.2 6597
4 EX-32.1 d483795dex321.htm EX-32.1 3176
5 EX-32.2 d483795dex322.htm EX-32.2 3169
  Complete submission text file 0001193125-23-276713.txt   5386666

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA vinc-20230930.xsd EX-101.SCH 30928
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vinc-20230930_cal.xml EX-101.CAL 29019
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vinc-20230930_def.xml EX-101.DEF 185588
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20230930_lab.xml EX-101.LAB 317921
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20230930_pre.xml EX-101.PRE 267169
52 EXTRACTED XBRL INSTANCE DOCUMENT d483795d10q_htm.xml XML 844362
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

IRS No.: 833197402 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39244 | Film No.: 231401928
SIC: 2834 Pharmaceutical Preparations